Teva Pharma (TEVA) Completes Acquisition of Allergan's Anda

October 3, 2016 10:00 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has completed its acquisition of Anda, Inc., a leading distributor of generic pharmaceuticals in the U.S., from Allergan plc.

“We are pleased that Anda, Inc., one of the leading distributors of generic medicines in the U.S., is now part of Teva. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for our business and for our extensive supply chain network in particular,” said Siggi Olafsson, President & CEO of Global Generic Medicines. “This acquisition enables us and our customers to provide more patients throughout the country with access to generic medicines."

“We are excited to become part of Teva’s distribution network to support our customers and patients across the country,” said Charles D. Phillips, President & CEO of Anda. “By joining forces with Teva, Anda’s product offerings will significantly increase and we will be able to reach more patients in the United States.”

Teva currently has over 300 product registrations pending FDA approval and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U.S. Currently, one-of-every six generic prescriptions dispensed in the U.S. is filled with a Teva product.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments, Mergers and Acquisitions

Related Entities

Definitive Agreement

Add Your Comment